Clinical Trial Update: SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial investigating SBRT plus pembrolizumab and trametinib for pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• SBRT (stereotactic body radiotherapy)
• Trametinib (trametinib)

Snippet

Sponsor: Changhai Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-02-16